Alnylam Pharmaceuticals
ALNY
#643
Rank
C$45.71 B
Marketcap
$353.16
Share price
-1.30%
Change (1 day)
73.68%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.96. In 2022 the company made an earnings per share (EPS) of -$13.47 a decrease over its 2021 EPS that were of -$10.44.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-59.19%
2022-$13.4729.03%
2021-$10.44-3.36%
2020-$10.80-8.48%
2019-$11.807.67%
2018-$10.9639.74%
2017-$7.8512.94%
2016-$6.9538.84%
2015-$5.00-32.88%
2014-$7.45259.44%
2013-$2.07-31.25%
2012-$3.0252.94%
2011-$1.9730.77%
2010-$1.51-8.77%
2009-$1.6578.13%
2008-$0.93-70.78%
2007-$3.1899.09%
2006-$1.60-43.88%
2005-$2.84-82.33%
2004-$16.09-59.23%
2003-$39.46

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.47-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$54.18-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$11.35 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.39-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.45-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.42-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.61-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.90-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel